JAK2 and colorectal cancer: Our data demonstrate that IL-6-induced autophagy contributes to the effectiveness of chemotherapy drug responses in colorectal cancer, and in combination with autophagy inhibitors or pharmacological agents targeting the IL-6/JAK2/BECN1 signaling pathway may represent a potential clinical therapy strategy.